Publications by authors named "Fadi Braiteh"

Claim this Profile
E
Exploring decisional control preferences in older patients with cancer and their caregivers.
Sofiia Hryniv, Elizabeth Gilbride, William Consagra, Supriya Mohile, Sule Yilmaz, Fadi S Braiteh

J Geriatr Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L Siu, Patricia LoRusso

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Shubham Pant, Erika Hamilton, Susanna V Ulahannan, James F Strauss, Fadi S Braiteh

Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
William D Tap, Arun S Singh, Stephen Patrick Anthony, Mike Sterba, Chao Zhang, Fadi Braiteh

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.
Siwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson, Xiao Wang, Alison Forgie

Target Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Daniel P Petrylak, Yohann Loriot, David R Shaffer, Fadi Braiteh, John Powderly

Clin Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and Ipilimumab Combination Therapy for Second-Line Treatment of Hepatocellular Carcinoma.
Fadi Braiteh

Gastroenterol Hepatol (N Y)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma.
Sant P Chawla, Sanjay Goel, Warren Chow, Fadi Braiteh, Arun S Singh

Clin Cancer Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Sarina A Piha-Paul, Matthew H Taylor, Daniel Spitz, Lee Schwartzberg, J Thaddeus Beck, Fadi Braiteh

Oncotarget· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Ignacio Garrido-Laguna, Ian Krop, Howard A Burris, Erika Hamilton, Fadi Braiteh

Int J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
Zorawar S Noor, Jonathan W Goldman, William E Lawler, Bijoy Telivala, Fadi Braiteh

Lung Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Joyce F Liu, Michael Gordon, Jennifer Veneris, Fadi Braiteh, Ani Balmanoukian

Gynecol Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Melissa L Johnson, Fadi Braiteh, Juneko E Grilley-Olson, Jeffrey Chou, Jasmine Davda

JAMA Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A Emens, Cristina Cruz, Joseph Paul Eder, Fadi Braiteh, Cathie Chung

JAMA Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, Christian Cotsoglou, William P Harris, Fadi Braiteh

Br J Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Li-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Fadi S Braiteh

Eur J Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis.
Sachdev P Thomas, Lauren E Jacobson, Anthony R Victorio, Theresa N Operaña, Brock E Schroeder, Fadi Braiteh

JCO Precis Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Carlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang

Am J Hematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.
Alexa B Schrock, Dean Pavlick, Samuel J Klempner, Jon H Chung, Brady Forcier, Fadi Braiteh

Clin Cancer Res· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Daniel P Petrylak, Thomas Powles, Joaquim Bellmunt, Fadi Braiteh, Yohann Loriot

JAMA Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signature program: a platform of basket trials.
Eric D Slosberg, Barinder P Kang, Julio Peguero, Matthew Taylor, Todd M Bauer, Fadi Braiteh

Oncotarget· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States.
Xiaolong Jiao, Sonia Pulgar, Marley Boyd, Fadi Braiteh, Beloo Mirakhur

Pancreas· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Sunil R Hingorani, Lei Zheng, Andrea J Bullock, Tara E Seery, William P Harris, Fadi Braiteh

J Clin Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of early-line -paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis.
Reshma L Mahtani, Monika Parisi, Stefan Glück, Quanhong Ni, Siyeon Park, Fadi Braiteh

Cancer Manag Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Fadi Braiteh

Oncologist· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis